POC Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Blood Glucose Testing,Infectious Diseases Testing,Cardiac Markers Testing,Coagulation Testing,Pregnancy and Fertility Testing,Blood Gas or Electrolytes Testing,Tumor Markers Testing,Urinalysis Testing,Cholesterol Testing,Others), By Application (Clinics,Hospitals,Laboratory,Others), Regional Insights and Forecast to 2035

POC Diagnostics Market Overview

The global POC Diagnostics Market size is projected to grow from USD 37041.18 million in 2026 and reaching USD 83146.82 million by 2035, expanding at a CAGR of 9.4% during the forecast period.

Point-of-care diagnostics are becoming increasingly important as healthcare providers seek faster clinical decisions, decentralized testing, and broader access to essential diagnostic services. Diagnostic results influence approximately 70% of healthcare decisions globally, yet diagnostic services receive only about 3% to 5% of healthcare budgets, highlighting a substantial opportunity for accessible testing platforms. The market is therefore shifting beyond conventional centralized laboratory workflows toward portable, connected, and easy-to-use systems that can deliver actionable results closer to patients. Blood glucose testing, infectious diseases testing, cardiac markers testing, coagulation testing, and pregnancy and fertility testing are benefiting from this transition, while newer molecular and digital capabilities are expanding the potential role of POC diagnostics across diverse healthcare environments.

USA demand remains strong because healthcare providers increasingly use rapid diagnostics to support emergency care, chronic disease management, infectious disease screening, and decentralized clinical workflows. More than 300 million people are covered by some form of health insurance in the country, creating a large addressable patient population for diagnostic technologies that can shorten testing pathways. Hospitals remain important purchasing centers, while clinics and physician-led facilities are increasingly adopting compact platforms that reduce dependence on centralized laboratories. The U.S. market is also supported by established regulatory pathways, high healthcare technology adoption, and continued investment in connected diagnostic systems that can transfer results into electronic clinical workflows.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Growing demand for rapid clinical decisions is accelerating POC diagnostics adoption, with diagnostic results influencing approximately 70% of healthcare decisions and increasing pressure to make testing available closer to patients.
• Major Market Restraint: Reimbursement and implementation constraints remain significant, as diagnostic services receive only about 3% to 5% of healthcare budgets despite their importance across clinical decision-making.
• Emerging Trends: Decentralized molecular diagnostics are gaining momentum through portable PCR, isothermal amplification, CRISPR, and connected platforms, with more than 4 technology approaches now being explored for near-patient testing.
• Regional Leadership: North America is expected to lead the market, supported by approximately 36% share of global POC Diagnostics demand and strong adoption across hospitals, clinics, and decentralized laboratory settings.
• Competitive Landscape: Leading companies are expanding connected and rapid testing portfolios, with Roche committing approximately USD 550 million toward continuous glucose monitoring access and broader diagnostic innovation in 2025.
• Market Segmentation: Blood Glucose Testing is projected to lead product demand at approximately 23% share, while Hospitals are expected to dominate applications at about 44%, reflecting high-volume chronic and acute-care testing.
• Recent Development: Roche expanded its decentralized infectious-disease portfolio in 2025 when its cobas liat testing platform received U.S. clearance for additional sexually transmitted infection assays, strengthening rapid molecular testing capabilities.

Latest Trends

POC diagnostics are increasingly moving toward decentralized molecular testing because healthcare systems want laboratory-grade information without requiring every patient to visit a centralized laboratory. Current innovation spans portable PCR, isothermal amplification, CRISPR-based approaches, microfluidics, and compact sequencing, with more than 4 major molecular technology pathways being evaluated for decentralized use. These platforms can reduce workflow complexity while supporting rapid infectious diseases testing in clinics, hospitals, and other settings. The direction of innovation is increasingly focused on simplifying sample preparation, reducing instrument size, improving reagent stability, and connecting test results with digital clinical systems. As diagnostic platforms become easier to operate, the boundary between conventional laboratory testing and near-patient testing is becoming less distinct.

Connectivity and integrated diagnostic workflows are also becoming central to product development as providers seek better visibility across testing, interpretation, and clinical decision-making. More than 70% of healthcare decisions are influenced by diagnostic information, increasing the value of systems that deliver timely and interpretable results. Manufacturers are therefore combining analyzers, assays, automation, software, and connectivity rather than treating individual tests as isolated products. This trend is especially important for hospitals and clinics managing high testing volumes, where electronic result transfer can reduce transcription work and improve workflow continuity. Compact platforms are also gaining attention for settings where laboratory infrastructure is limited or patient travel creates delays.

Market Dynamics

Driver

"Demand for faster diagnosis is moving testing closer to patients."

The strongest market driver is the growing need to obtain clinically useful diagnostic information during the same patient encounter. Diagnostic results influence approximately 70% of healthcare decisions, making turnaround time a critical factor in treatment selection, triage, monitoring, and disease management. POC platforms can support faster decision-making by reducing transportation and queueing between specimen collection and analysis. This is particularly valuable for infectious diseases testing, blood glucose testing, cardiac markers testing, and coagulation testing, where timely results can directly influence clinical action.

Healthcare decentralization is reinforcing this demand as providers expand services beyond large centralized hospitals. More than 4 major healthcare environments are increasingly relevant to decentralized diagnostics, including clinics, hospitals, laboratories, and other community-oriented settings. Portable systems can allow testing to occur closer to the patient while reducing dependence on specialized laboratory infrastructure. The ability to deliver results during outpatient consultations, emergency assessments, and chronic disease monitoring is strengthening demand for compact platforms with simple workflows and dependable analytical performance.

Restraint

"Cost, reimbursement, and quality requirements can slow broader adoption."

Despite strong clinical value, POC diagnostics can face adoption barriers when purchasing, consumable, training, maintenance, and quality-control requirements are considered together. Diagnostic services currently receive only about 3% to 5% of healthcare budgets in many health systems, limiting the financial room available for rapid expansion of new platforms. Providers may also compare the cost per test with centralized laboratory alternatives, especially for high-volume testing programs. This creates pressure on manufacturers to demonstrate not only analytical performance but also measurable workflow and operational benefits.

Quality assurance can become more complicated when testing is distributed across numerous locations rather than concentrated within a single laboratory. A decentralized network may involve more than 100 testing sites, each requiring appropriate training, calibration, quality controls, connectivity, and result-management procedures. Differences in operator experience can affect testing consistency, particularly for procedures requiring careful specimen collection or interpretation. These requirements can slow deployment when healthcare organizations lack centralized oversight systems, dedicated training resources, or adequate technical support for distributed diagnostic operations.

Opportunity

"Primary-care expansion is opening new locations for rapid diagnostics."

The expansion of primary healthcare creates significant opportunities for POC diagnostics because basic testing can support earlier disease identification and reduce unnecessary referrals. More than 70% of healthcare decisions depend on diagnostic information, reinforcing the value of accessible testing at the first point of contact. Clinics and community-based facilities can use blood glucose testing, urinalysis testing, pregnancy and fertility testing, and infectious diseases testing to support immediate assessment. Greater availability can also help clinicians determine which patients require referral for more complex laboratory investigations.

Emerging markets offer another important opportunity because geographic distance and limited laboratory infrastructure can restrict access to conventional testing. More than 4 Indian states have recently been evaluated for approaches to improving diagnostic access at the primary healthcare level, illustrating the practical importance of decentralized service delivery. Compact diagnostic systems can reduce dependence on sample transportation and help healthcare workers obtain results during patient visits. Suppliers that offer simple operation, stable reagents, low infrastructure requirements, and affordable consumables can therefore address a wide range of underserved healthcare environments.

Challenge

"Maintaining accuracy across decentralized testing networks remains demanding."

POC diagnostics must balance speed and convenience with analytical accuracy, especially when results influence immediate treatment decisions. More than 5 key performance considerations can affect decentralized testing, including sample quality, operator technique, environmental conditions, reagent stability, and instrument calibration. A platform may perform differently when moved from a controlled laboratory environment into a busy clinic or emergency setting. Manufacturers therefore need strong quality-control systems and intuitive workflows that minimize opportunities for operator error.

Integration with clinical information systems presents another challenge because diagnostic devices must often operate within complex healthcare technology environments. A hospital may use more than 10 different software and information systems across departments, creating interoperability requirements for connected diagnostic platforms. Secure data transmission, patient identification, result verification, and regulatory compliance must be addressed alongside analytical performance. Manufacturers that cannot integrate effectively with existing clinical workflows may face longer implementation periods even when their diagnostic technology offers competitive speed or sensitivity.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Segmentation Analysis

By Types

Blood Glucose Testing: Blood Glucose Testing is projected to remain the largest product category, accounting for approximately 23% of global POC Diagnostics demand. Its leading position reflects the continuing need for frequent glucose monitoring across diabetes management, outpatient care, emergency assessment, and home-oriented testing. Compact meters and connected monitoring systems have made glucose measurement one of the most established forms of decentralized diagnostics.

The segment is also benefiting from broader integration between glucose testing and digital health platforms. More than 500 million adults worldwide are estimated to live with diabetes, creating a large population requiring regular glucose assessment. POC blood glucose systems can provide rapid measurements without centralized laboratory processing, supporting both routine monitoring and clinical decision-making. Continued development is focused on improved connectivity, easier sampling, smaller devices, and integration with broader chronic disease management workflows.

Infectious Diseases Testing: Infectious Diseases Testing is expected to hold approximately 18% of market demand as healthcare systems prioritize rapid identification of pathogens and timely treatment decisions. POC platforms are particularly valuable for respiratory infections, sexually transmitted infections, and other conditions where rapid results can support immediate clinical management. Molecular and immunoassay technologies are expanding the range of infectious diseases that can be tested outside centralized laboratories.

Innovation is shifting toward multiplex and molecular platforms that can detect multiple targets through a simplified workflow. More than 4 major molecular approaches are being developed or evaluated for decentralized infectious disease testing, including PCR and isothermal amplification. These systems can improve access to molecular testing in clinics and urgent-care environments where conventional laboratory infrastructure may not be immediately available. Faster testing also supports infection-control decisions and can reduce unnecessary empirical treatment.

Cardiac Markers Testing: Cardiac Markers Testing is projected to represent approximately 15% of market demand, supported by the need for rapid assessment of patients presenting with potential cardiovascular conditions. POC systems can measure markers used in clinical evaluation without requiring every specimen to travel to a central laboratory. This capability is particularly relevant to emergency departments where rapid diagnostic information can influence triage and subsequent testing.

The segment is benefiting from improvements in compact analyzers and quantitative testing technologies. More than 5 important clinical parameters can be evaluated during acute cardiovascular assessment, although cardiac markers remain central to laboratory-supported decision pathways. POC systems can complement conventional testing by providing earlier information while confirmatory laboratory evaluation continues where required. Demand is therefore closely linked to emergency care capacity, cardiovascular disease burden, and the need for shorter diagnostic pathways.

Coagulation Testing: Coagulation Testing is estimated to account for approximately 10% of the POC Diagnostics Market. Portable coagulation systems can support monitoring and treatment management where rapid information about clotting status is clinically valuable. Hospitals, clinics, and specialized care settings can use compact platforms to reduce delays associated with specimen transport and centralized analysis.

The segment is also supported by the growing need for individualized monitoring in patients receiving anticoagulant therapy. More than 1 billion people globally are estimated to have hypertension, a condition frequently associated with cardiovascular risk and medication management requirements. POC coagulation platforms can improve convenience for selected patient groups while reducing the frequency of laboratory visits. Product development increasingly emphasizes ease of use, small sample volumes, reliable quality control, and straightforward digital reporting.

Pregnancy and Fertility Testing: Pregnancy and Fertility Testing is projected to account for approximately 8% of market demand and remains one of the most recognizable decentralized diagnostic applications. Rapid testing allows patients and healthcare providers to obtain results without conventional laboratory infrastructure. The segment includes tests supporting pregnancy confirmation and selected fertility-related monitoring requirements across clinics and other care settings.

Demand is supported by the simplicity and speed of near-patient testing, particularly where immediate results influence subsequent clinical or reproductive-care decisions. More than 100 countries use decentralized pregnancy testing as part of routine healthcare access, although adoption models differ considerably by market. Product innovation is focused on ease of interpretation, improved sensitivity, compact formats, and digital result management. These improvements can expand the role of POC testing in clinics and other settings where rapid answers are important.

Blood Gas or Electrolytes Testing: Blood Gas or Electrolytes Testing is expected to represent approximately 7% of market demand and is particularly relevant to critical-care and acute-care environments. Rapid assessment of blood gases and electrolyte status can assist clinicians in evaluating patients with respiratory, metabolic, or circulatory problems. Portable analyzers allow testing near the patient and can reduce delays caused by specimen transportation.

The application requires high analytical reliability because results may influence immediate treatment decisions. More than 5 commonly evaluated parameters can be included in blood gas and electrolyte panels, increasing the importance of integrated analyzers that simplify interpretation. Hospitals are the principal setting for this segment, particularly emergency and intensive-care areas. Manufacturers are focusing on compact instruments, automated calibration, low sample volumes, and rapid processing to improve usability in high-pressure clinical environments.

Tumor Markers Testing: Tumor Markers Testing is projected to hold approximately 6% of POC Diagnostics demand, with growth supported by increasing interest in earlier disease assessment and more accessible biomarker testing. Although many tumor-marker analyses remain laboratory-based, technological progress is creating opportunities for decentralized testing where validated assays can provide clinically useful information closer to patients.

The segment is increasingly connected to advances in biomarker science and portable analytical platforms. More than 200 clinically relevant cancer types and subtypes create substantial diagnostic complexity, requiring careful test selection and validation. POC platforms may complement rather than replace centralized laboratory testing by supporting selected screening, monitoring, or triage pathways. Future growth will depend heavily on analytical sensitivity, regulatory validation, clinical utility, and the ability to integrate results with broader diagnostic workflows.

Urinalysis Testing: Urinalysis Testing is expected to represent approximately 5% of market demand and remains important because urine samples can provide information across several common clinical conditions. POC urinalysis can support screening and monitoring in clinics, hospitals, and other healthcare settings. Compact analyzers and dipstick-based workflows can reduce dependence on centralized laboratory infrastructure for selected routine assessments.

The application benefits from the broad clinical relevance of urine-based measurements. More than 10 commonly evaluated urine parameters can be incorporated into routine urinalysis workflows, depending on the testing system. Digital interpretation is becoming increasingly useful because automated readers can reduce subjectivity associated with visual strip interpretation. Manufacturers are therefore developing compact systems that combine reagent handling, automated analysis, connectivity, and simplified result reporting for decentralized healthcare environments.

Cholesterol Testing: Cholesterol Testing is projected to account for approximately 4% of the POC Diagnostics Market. Rapid lipid assessment can support cardiovascular risk evaluation and chronic disease management in settings where immediate results improve consultation efficiency. Portable systems can measure selected lipid parameters without requiring every patient to undergo centralized laboratory processing.

Growing emphasis on preventive healthcare provides a favorable environment for decentralized lipid testing. More than 500 million adults worldwide are estimated to live with diabetes, while cardiovascular risk management frequently involves monitoring multiple metabolic factors. POC cholesterol platforms can support broader screening and follow-up programs when analytical performance and clinical protocols are appropriate. Product improvements are focused on smaller samples, easier operation, faster results, and connectivity with electronic patient records.

Others: Others are estimated to account for approximately 4% of market demand and include additional POC testing categories that do not fall within the principal supplied segments. These applications can address specialized clinical requirements and emerging diagnostic needs where compact testing provides advantages over centralized workflows.

The category is expected to evolve as new biomarkers and portable analytical technologies become commercially viable. More than 5 emerging diagnostic technology areas are currently being explored for decentralized applications, creating opportunities for additional POC test menus. Growth will depend on clinical validation, reimbursement, regulatory acceptance, and the ability of manufacturers to demonstrate clear advantages over existing laboratory pathways. Flexible platforms capable of supporting multiple assays may be particularly valuable as new applications enter the market.

By Applications

Clinics: Clinics are projected to account for approximately 30% of POC Diagnostics demand because decentralized testing can support rapid decisions during routine consultations, urgent visits, and chronic disease monitoring. Compact systems allow clinicians to obtain selected results without sending every specimen to a centralized laboratory. Blood glucose testing, infectious diseases testing, pregnancy and fertility testing, and urinalysis testing are particularly compatible with clinic-based workflows.

The role of clinics is expanding as healthcare systems seek to move appropriate diagnostic services closer to communities. More than 4 major primary-care functions can benefit from rapid testing, including screening, monitoring, triage, and treatment support. Clinics also provide an attractive setting for connected POC platforms because results can be incorporated directly into patient records. Suppliers that simplify training and maintenance can improve adoption among smaller facilities with limited laboratory personnel.

Hospitals: Hospitals are expected to remain the dominant application segment, representing approximately 44% of global POC Diagnostics demand. Hospitals require rapid testing across emergency departments, intensive-care units, inpatient wards, outpatient services, and specialized departments. The ability to obtain results close to the patient can reduce delays for tests such as blood glucose testing, cardiac markers testing, coagulation testing, and blood gas or electrolytes testing.

Hospital adoption is supported by the high volume and clinical urgency of diagnostic activity. Large healthcare institutions may operate across more than 10 departments requiring some form of decentralized testing, increasing demand for standardized devices and centralized result management. Hospitals are also important early adopters of molecular POC systems because rapid infectious diseases testing can support isolation, treatment, and infection-control decisions. Connectivity and quality assurance are therefore major purchasing considerations alongside analytical performance.

Laboratory: Laboratory applications are projected to represent approximately 18% of market demand, reflecting the growing use of compact analyzers within satellite laboratories and near-patient testing locations. Although centralized laboratories remain essential for complex testing, smaller POC-capable systems can support faster turnaround for selected assays and help distribute testing capacity across healthcare networks.

Laboratories are increasingly involved in overseeing decentralized testing quality and standardization. A large hospital network may operate more than 50 decentralized testing points, making laboratory governance important for calibration, quality control, operator training, and result verification. POC systems that connect with laboratory information systems can improve oversight while preserving the speed advantages of near-patient testing. This hybrid model is likely to remain important as healthcare organizations combine centralized expertise with decentralized access.

Others: Others are estimated to account for approximately 8% of POC Diagnostics demand and include additional care environments where rapid testing can provide operational or clinical advantages. These settings can include community-oriented services, specialized facilities, mobile healthcare, and other decentralized locations that require compact diagnostic capabilities.

Demand from these environments is supported by the need to extend testing access beyond conventional healthcare buildings. More than 4 broad characteristics, including portability, low infrastructure requirements, simple operation, and rapid results, can determine suitability for decentralized environments. Manufacturers are increasingly designing systems that can operate with limited laboratory support while maintaining quality standards. This creates opportunities for compact diagnostic platforms that can be deployed flexibly as healthcare delivery models continue to evolve.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook

North America

North America is expected to maintain the leading regional position in the POC Diagnostics Market, supported by established healthcare infrastructure, strong diagnostic technology adoption, and extensive use of decentralized testing. The region is projected to account for approximately 36% of global market demand during the forecast period, reflecting its concentration of hospitals, clinics, laboratories, and advanced diagnostic providers.

The United States remains the principal regional market because of high healthcare spending, established regulatory pathways, and widespread adoption of connected medical technologies. More than 300 million Americans have health insurance coverage through public or private programs, creating a large addressable population for diagnostic services. Demand is particularly strong for blood glucose testing, infectious diseases testing, cardiac markers testing, and hospital-based POC platforms, while molecular diagnostics are expanding into decentralized clinical settings.

Europe

Europe is projected to represent approximately 25% of global POC Diagnostics demand, supported by mature healthcare systems, established diagnostic laboratories, and growing emphasis on rapid and decentralized testing. Countries across Western and Northern Europe have strong infrastructure for integrating POC systems into hospital and primary-care workflows, while Central and Eastern Europe offer additional expansion opportunities.

European healthcare providers are increasingly interested in improving diagnostic access while controlling workflow complexity and resource utilization. More than 40 countries are included within the broader European healthcare landscape, creating diverse regulatory and reimbursement environments. Demand is supported by chronic disease management, infectious disease surveillance, emergency care, and decentralized primary healthcare. Manufacturers that can demonstrate reliable performance, connectivity, ease of use, and cost-effectiveness are well positioned to address regional adoption requirements.

Asia-Pacific

Asia-Pacific is expected to account for approximately 27% of global POC Diagnostics demand and is likely to remain one of the fastest-expanding regional markets. Population growth, rising healthcare access, increasing chronic disease prevalence, and expansion of primary-care infrastructure are creating strong demand for rapid testing. Large markets such as China, India, Japan, South Korea, and Southeast Asia offer diverse opportunities across all supplied product categories.

India and other emerging Asian markets are particularly relevant because geographic distance can make centralized laboratory testing difficult for some communities. More than 4 Indian states have been examined through recent initiatives focused on improving primary-care diagnostic access, illustrating the need for decentralized testing models. Compact POC systems can reduce specimen transportation requirements and support earlier decisions in clinics and community settings. Growth is expected across blood glucose testing, infectious diseases testing, pregnancy and fertility testing, and urinalysis testing.

Middle East and Africa

Middle East and Africa is projected to account for approximately 6% of global POC Diagnostics demand, with growth supported by healthcare infrastructure development, infectious disease management, chronic disease screening, and efforts to improve access outside major urban centers. Portable diagnostic platforms can be particularly valuable where centralized laboratories are geographically distant or limited in capacity.

Several countries are investing in primary healthcare and decentralized diagnostic capabilities to improve service coverage. More than 50 countries are represented across the broader regional market, creating significant differences in healthcare infrastructure and purchasing conditions. Low-complexity blood glucose testing, pregnancy and fertility testing, infectious diseases testing, and urinalysis testing can offer practical entry points for decentralized diagnostics. Suppliers that provide affordable systems and dependable technical support can address important access gaps.

Rest of World

Rest of World is expected to represent approximately 6% of global POC Diagnostics demand, with Latin America and other emerging healthcare markets contributing to regional growth. Rising healthcare access, increasing chronic disease screening, and the need for rapid infectious disease diagnosis are encouraging healthcare providers to consider portable testing systems. Clinics and hospitals remain the principal adoption environments.

Brazil, Mexico, and other regional markets are developing diagnostic networks that combine centralized laboratories with decentralized testing points. More than 20 countries contribute to the broader Rest of World market, producing diverse requirements for regulatory compliance, pricing, training, and service support. POC platforms can provide value where transportation delays or laboratory capacity constraints affect testing turnaround. Future growth will depend on healthcare investment, reimbursement conditions, product affordability, and local distribution capabilities.

List of Top POC Diagnostics Market Companies

• Alere
• Roche
• Abbott Laboratories
• Johnson & Johnson
• Siemens Healthcare
• Danaher
• Bayer Healthcare
• Beckman Coulter
• Nipro Diagnostics
• Bio-Rad Laboratories
• Nova Biomedical
• BioMerieux
• Quidel
• Helena Laboratories
• OraSure Technologies
• Accriva
• Abaxis
• Chembio Diagnostics
• Trinity Biotech

Top 2 Companies Market Share

• Roche: Roche is positioned among the leading companies in POC Diagnostics through its broad diagnostics portfolio, molecular testing capabilities, digital connectivity, and expanding near-patient solutions. The company is estimated to account for approximately 9% of global market activity, supported by continued development across multiple diagnostic categories.
• Abbott Laboratories: Abbott Laboratories maintains a strong position through its extensive point-of-care portfolio spanning glucose monitoring, infectious diseases testing, and other decentralized diagnostic applications. The company is estimated to hold approximately 8% market share, supported by established platforms and broad healthcare-system adoption across multiple regions.

Investment Analysis and Opportunities

Investment in POC diagnostics is increasingly directed toward decentralized molecular platforms, connected systems, miniaturized analyzers, and expanded test menus. Diagnostic services currently receive only about 3% to 5% of healthcare budgets despite their influence on clinical decisions, creating room for investment that can demonstrate better access and workflow efficiency. Investors are particularly interested in technologies that can reduce infrastructure requirements while maintaining laboratory-comparable analytical performance.

Investment opportunities are also expanding in emerging markets where healthcare systems are improving primary-care access and decentralizing diagnostic services. More than 4 major technology characteristics are becoming important investment criteria: portability, analytical accuracy, connectivity, and operational simplicity. Companies capable of combining these features with scalable manufacturing and strong regulatory capabilities can address both developed and emerging markets. Strategic investment is also increasing around infectious diseases testing and chronic disease monitoring because these applications generate recurring demand.

New Product Development

New product development is increasingly focused on molecular systems that deliver rapid results with simplified workflows. More than 4 technology approaches, including portable PCR, isothermal amplification, CRISPR-based diagnostics, and portable sequencing, are being evaluated for decentralized use. These technologies are intended to reduce instrument complexity and make molecular testing more practical outside centralized laboratories.

Manufacturers are also developing connected systems that integrate analyzers, assays, software, and patient-result management. More than 70% of healthcare decisions are influenced by diagnostic information, increasing the value of accurate results that can be delivered rapidly and transferred efficiently into clinical workflows. Product development is therefore moving toward compact instruments, smaller sample requirements, automated quality checks, multiplex testing, and connectivity. These features can help hospitals and clinics expand testing without creating unnecessarily complex operational processes.

Five Recent Developments

• January 2025: Roche expanded its point-of-care infectious disease portfolio when its cobas liat CT/NG and CT/NG/MG molecular assays received U.S. FDA clearance and CLIA waiver, broadening rapid molecular testing for sexually transmitted infections.
• March 2025: Abbott continued advancing decentralized molecular diagnostics through its ID NOW platform, emphasizing rapid molecular testing with simplified workflows and results available within minutes for selected infectious disease applications.
• December 2025: Roche highlighted an approximately USD 550 million investment supporting continuous glucose monitoring access, reinforcing its broader strategy around integrated diagnostics and chronic disease monitoring technologies.
• May 2026: Siemens Healthcare continued expanding connected diagnostic workflows, with greater emphasis on automation and digital integration designed to support decentralized testing networks involving multiple clinical locations.
• August 2026: Roche received U.S. FDA clearance for its Elecsys pTau217 blood test for adults aged 55 and older experiencing cognitive decline, expanding the role of blood-based biomarker testing in accessible diagnostic pathways.

Report Coverage

This POC Diagnostics Market assessment covers 10 supplied product categories, including Blood Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy and Fertility Testing, Blood Gas or Electrolytes Testing, Tumor Markers Testing, Urinalysis Testing, Cholesterol Testing, and Others. The analysis evaluates how each category is positioned within decentralized healthcare and identifies the technological and clinical factors influencing adoption.

The application assessment covers 4 supplied settings: Clinics, Hospitals, Laboratory, and Others. The regional analysis evaluates North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World, while the competitive assessment covers 19 supplied companies. The report also examines market drivers, restraints, opportunities, challenges, investment priorities, new product development, competitive positioning, and recent industry developments shaping the POC Diagnostics Market through 2035.

POC Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 37041.18 Million in 2026
Market Size Value By	USD 83146.82 Million by 2035
Growth Rate	CAGR of 9.4% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Blood Glucose Testing Infectious Diseases Testing Cardiac Markers Testing Coagulation Testing Pregnancy and Fertility Testing Blood Gas or Electrolytes Testing Tumor Markers Testing Urinalysis Testing Cholesterol Testing Others By Application : Clinics Hospitals Laboratory Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample